Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for MASLD, and in 2024, Efruxifermin and Pegozafermin entered Phase 3 clinical trials. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.